Linepemat

Linepemat (INNTooltip International Nonproprietary Name), also known as 3-(2,3-difluorophenoxy)azetidine, is a drug described as a "nootrope".^[2][3][4] It has been found to produce hyperlocomotion in rodents as well as to dose-dependently reverse the hypolocomotion induced by the monoamine depleting agent tetrabenazine in rodents.^[3] The drug was patented by Integrative Research Laboratories (IRL) in January 2025 with the application of treatment of apathy^[3][4] and its INNTooltip International Nonproprietary Name was registered in January 2026.^[2] IRL is developing a drug with the developmental code name IRL757 for treatment of apathy in Parkinson's disease and neurodegenerative disorders.^{[1][5][6][7][8][9]} As of January 2026, IRL757 is in phase 1/2 clinical trials for Parkinson's disease and phase 1 trials for neurodegenerative disorders, having entered phase 1/2 trials by December 2025.^[1] Linepemat is very similar in chemical structure to pirepemat (IRL752), another nootropic drug candidate.^[3]

Other names3-(2,3-Difluorophenoxy)azetidine

Routes of
administrationOral^[1]

Drug classNootrope

CAS Number

• 1211876-03-7

Quick facts Clinical data, Other names ...

Linepemat

Clinical data
Other names	3-(2,3-Difluorophenoxy)azetidine
Routes of administration	Oral[1]
Drug class	Nootrope
Identifiers
IUPAC name 3-(2,3-difluorophenoxy)azetidine
CAS Number	1211876-03-7
PubChem CID	53407685
ChemSpider	26546723
UNII	AES8RB3JS4
ChEMBL	ChEMBL6047610
Chemical and physical data
Formula	C9H9F2NO
Molar mass	185.174 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1C(CN1)OC2=C(C(=CC=C2)F)F
InChI InChI=1S/C9H9F2NO/c10-7-2-1-3-8(9(7)11)13-6-4-12-5-6/h1-3,6,12H,4-5H2 Key:TXTVXNRODZFMEX-UHFFFAOYSA-N

Close